National Peroxide FY26 turnaround, ₹7 final dividend

Share price snapshot on April 30, 2026

National Peroxide’s share price stood at ₹460 at 15:29 on April 30, 2026. During the session, the stock moved between ₹421.05 and ₹465.00. On a 52-week basis, it has traded in a wider range of ₹350.00 to ₹770.00. These levels set the immediate context for the company’s year-end announcements and corporate updates.

Board actions announced on April 30

National Peroxide disclosed two key outcomes dated April 30, 2026. First, the Board recommended a final dividend of ₹7 per equity share for FY26, described as a 70% dividend, subject to shareholder approval at the upcoming AGM. Second, the company announced a finance leadership transition involving the roles of CFO and CRO.

The corporate actions align with the Board’s April 30 agenda item listed as “Audited Results & Final Dividend”. The company also indicated earlier that the April 30 Board meeting would consider and approve audited financial results for the quarter and year ended March 31, 2026, and discuss a dividend recommendation.

FY2026 results: turnaround in reported profitability

National Peroxide reported a FY2026 turnaround with total income of ₹295.68 crore (₹29,568.37 lakh). The company reported net profit after tax of ₹11.04 crore (₹1,103.71 lakh) for FY2026, compared to a loss of ₹2.25 crore (₹224.64 lakh loss) in FY2025. It also reported earnings per share of ₹19.20 (basic and diluted) for FY2026, versus a loss per share of ₹3.91 in FY2025.

These figures show a shift from loss to profit on an annual basis. The FY2026 dividend recommendation came alongside these audited results and will require shareholder approval.

Q3 FY26 and nine-month numbers that preceded the year-end

For Q3 FY2026, the company reported revenue from operations of ₹69.09 crore (₹6,908.70 lakh) and profit after tax of ₹1.83 crore (₹183.23 lakh). For the nine months ended December 31, 2025, it reported revenue from operations of ₹204.03 crore (₹20,402.85 lakh) and profit after tax of ₹3.11 crore (₹310.85 lakh). The company also disclosed an exceptional item of ₹0.58 crore (₹58.15 lakh) in Q3 due to past service costs linked to the Social Security Code.

A separate results note stated Q3 FY26 revenue from operations rose 11.15% year-on-year to ₹6,908.70 lakh, and Q3 FY26 net profit compared to a loss in the corresponding quarter of the previous year. Alongside these results, the Board approved the appointment of a new Company Secretary and Compliance Officer.

CFO and CRO transition: effective dates and continuity

Under a Regulation 30 (LODR) filing on management change, National Peroxide stated that Interim CFO and CRO Mr. Amit Goriwale will step down effective May 31, 2026. The company said Mr. Chirag Kothari has been appointed as the new CFO and CRO effective June 1, 2026.

The disclosure also indicated this is a planned transition, with Mr. Goriwale continuing with the company in another role. Earlier, the company had announced Mr. Goriwale’s interim appointment as CFO and CRO effective December 18, 2025, with the interim role lasting until a permanent CFO was appointed.

Company Secretary appointment tied to Q3 results

Along with the Q3 FY26 Board outcome dated February 5, 2026, the company approved the appointment of Mr. Akshay Satasiya as Company Secretary and Compliance Officer and a Key Managerial Personnel, effective March 9, 2026. The disclosure described him as an Associate Member of the Institute of Company Secretaries of India with over 10 years of experience in compliance and governance.

This appointment came during a period where the company was also updating its finance leadership. Taken together, the filings show sequential changes across key governance and finance functions during FY26.

Corporate action calendar: key board dates

The company’s corporate actions list highlights multiple results-related Board dates across FY25 and FY26. The FY26 year-end Board date is April 30, 2026, while earlier FY26 dates include February 5, 2026 and January 28, 2026 for quarterly results. FY25 entries include November 3, 2025, July 29, 2025, May 6, 2025, and January 23, 2025.

The company also disclosed that a Board meeting originally scheduled for January 28, 2026 was deferred due to unavoidable circumstances, with a revised schedule to be communicated.

Credit view from FY25: downgrade and operating pressure

A separate note in the provided information said India Ratings downgraded National Peroxide’s bank loan facilities from ‘IND A’ to ‘IND A-’ with a Negative Outlook. It also cited that revenue declined 14% year-on-year to ₹286.90 crore (INR 2,869 million) in FY25, while EBITDA fell 50% to ₹15.20 crore (INR 152 million). The same note referenced a plan for diversification by FY26.

These FY25 datapoints provide context for why FY26’s return to reported profitability and the decision to recommend a final dividend are being closely tracked by investors.

Market impact and what investors will track next

The immediate market read-through includes the stock’s trading band on April 30 and its wider 52-week range. Corporate actions that can shape near-term investor attention include the AGM vote required to approve the ₹7 final dividend, and the CFO and CRO changeover effective from June 1, 2026.

Investors will also track how quarterly performance trends line up with the FY26 full-year outcome, given the company’s Q3 and nine-month disclosures and the exceptional item booked in Q3. Separately, the timeline of governance and finance leadership changes across December 2025 to June 2026 remains an important disclosure stream for public-market monitoring.

Conclusion

National Peroxide ended FY26 with a reported profit turnaround and a Board-recommended ₹7 per share final dividend, while also setting a clear timetable for a CFO and CRO transition from May 31 to June 1, 2026. The next formal milestone will be shareholder consideration of the dividend at the upcoming AGM, along with continued disclosures as the new finance leadership assumes charge.